Individual herpes outbreaks do heal on their own, usually within a couple of weeks, but the underlying infection never goes away. Herpes simplex virus (both HSV-1 and HSV-2) establishes a permanent, hidden residence inside nerve cells, where it remains for life. That distinction between a sore that heals and an infection that resolves is the source of enormous confusion, and it matters for everything from transmission risk to treatment decisions.
What “Clearing Up” Actually Means
When people ask whether herpes clears up, they usually mean one of two things. The first is whether a visible outbreak, the blisters and sores, will go away without treatment. The answer is yes. Your immune system fights the active virus in your skin, the sores crust over, and the tissue heals. In people with healthy immune systems, a genital herpes episode typically resolves within about two weeks, and cold sores on the lip follow a similar timeline.
The second question is whether the virus itself ever leaves your body. It does not. After the initial infection in skin or mucous membranes, the virus travels along nerve fibers into clusters of nerve cells called ganglia. For oral herpes, this is usually the trigeminal ganglia near the base of the skull; for genital herpes, the sacral ganglia near the base of the spine. Once there, the viral DNA settles into a quiet, dormant state inside the neuron’s nucleus, wrapped in proteins that silence its genes.
This dormant state, called latency, is remarkably stable. The viral genome persists as a silent loop of DNA, maintained in a form that the cell’s own machinery keeps switched off. Only a tiny fraction of viral genes remain active during latency.
Why the Virus Cannot Be Flushed Out
The hiding place is what makes herpes permanent. Neurons are long-lived cells that your body does not routinely replace, so the virus does not lose its home to normal cell turnover. And because the viral DNA is largely silent during latency, infected neurons look normal to the immune system. Your immune cells, particularly CD8+ T cells, do patrol the ganglia and help keep the virus suppressed, but they cannot eliminate the latent DNA without destroying the neuron itself.
After primary infection, the virus replicates in epithelial cells, and infectious virus shed from those cells enters sensory nerve endings. The viral capsid then travels by retrograde transport up the nerve fiber to the cell body, where the DNA enters the nucleus and transitions into a transcriptionally silent state maintained as heterochromatin.
This is a fundamentally different situation from, say, a bacterial skin infection that your immune system can wipe out entirely. The latent herpes genome is not producing the proteins that antibodies recognize. It is essentially invisible, waiting. Current antiviral drugs only target the virus when it is actively replicating. They have no effect on latent DNA sitting quietly inside a neuron.
Outbreaks Do Get Better Over Time
If the virus never leaves, you might expect outbreaks to stay just as bad forever. They usually don’t. For most people, the first outbreak is the worst, and recurrences become less frequent and less severe over the years. This is one reason many people believe the infection has “gone away.”
A study tracking genital HSV-2 shedding found that total viral shedding occurred on about a third of days in participants less than a year from their first episode, dropping to roughly one in five days for those one to nine years out, and about one in six days for those ten or more years past their first episode.
The pattern is real and consistent. Your immune system gets better at controlling reactivation over time, and the virus itself may become somewhat less aggressive in its attempts to reactivate. But “less frequent” is not “gone.” Even a decade after the first outbreak, the virus can still reactivate and shed.
The Silent Shedding Problem
One of the most important and least understood aspects of herpes is subclinical shedding: the virus reactivating and appearing on the skin’s surface without causing any visible sores or noticeable symptoms. This is how a large share of herpes transmission happens, because the person shedding the virus has no idea it is occurring.
Research comparing people with symptomatic and asymptomatic HSV-2 infection found that even those who had never noticed symptoms shed virus on about 10% of days sampled. People with a history of symptomatic outbreaks shed on about 20% of days. The amount of virus detected during subclinical episodes was similar regardless of whether someone had a history of symptoms, with median viral loads that were statistically indistinguishable between the two groups.
This is worth sitting with. A person who has never had a noticeable outbreak, who might reasonably think they are “fine” or even uninfected, can still shed enough virus to infect a partner. The virus does not need to produce a visible sore to be contagious. It periodically wakes up, travels back down the nerve to the skin, produces a small burst of virus, and retreats before any blister forms. Subclinical shedding rates do decline over the years, but they never reach zero.
What Triggers a Reactivation
The transition from latency back to active infection, called reactivation, is triggered by various forms of stress on the body. Known triggers include psychological stress, fever, sunburn, menstruation, and physical trauma to the area. These triggers share a common characteristic: they alter the chemical signaling environment inside neurons in ways that can destabilize the silencing of viral genes.
At the immune level, a drop in the normal T-cell-driven cytokine environment that keeps the virus suppressed can also tip the balance toward reactivation. This is why people who are immunocompromised, whether from chemotherapy, organ transplant medications, or HIV, tend to experience more frequent and more severe outbreaks. In these patients, herpes can present in unusual ways, including large, necrotizing skin lesions that do not respond to standard antiviral treatment.
For people with healthy immune systems, reactivation triggers are often unpredictable. Many people notice a pattern (stress at work, a sunburn, their menstrual cycle), but plenty of reactivations happen without any identifiable cause. The virus seems to periodically “test” the immune system’s defenses, and sometimes it breaks through.
Virus Type and Location Shape the Long-Term Experience
Not all herpes infections behave the same way. The virus type (HSV-1 versus HSV-2) and the location of infection interact to produce very different recurrence patterns. A classic study tracking patients after their first herpes episodes found striking differences in how often the virus came back depending on this combination.
Genital HSV-2 infections recurred most frequently, averaging about once every three months. Oral HSV-1 infections (the typical cold sore) recurred less often, roughly once every eight months. Genital HSV-1 infections were much more infrequent, averaging about once every four years. And oral HSV-2, the rarest combination, almost never recurred.
This matters practically. If you have genital HSV-1, your experience is likely to be very different from someone with genital HSV-2. The first outbreak may look similar, but the long-term recurrence rate for genital HSV-1 is dramatically lower. Many people with genital HSV-1 have one or two outbreaks and then never have another visible episode, which can reinforce the misconception that the infection has resolved. The virus is still latent in the sacral ganglia. It simply reactivates far less often in that anatomical location.
Antivirals Speed Healing but Don’t Cure
The standard antiviral medications for herpes, acyclovir and its prodrug valacyclovir, work by interfering with viral DNA replication. They are effective at shortening outbreaks and reducing their severity but have no impact on latent virus. A randomized trial comparing valacyclovir, acyclovir, and placebo for recurrent genital herpes found that both drugs shortened episodes by about a day compared to placebo, with median outbreak durations of roughly five days on medication versus six days without.
There are two ways to use these medications. Episodic therapy means taking the drug at the first sign of an outbreak and continuing for a few days. This approach modestly shortens the episode and can reduce severity, but it does not prevent the next one. Suppressive therapy means taking a daily dose continuously, regardless of whether symptoms are present. This approach is substantially more effective at preventing recurrences.
In a head-to-head comparison, suppressive valacyclovir reduced the risk of recurrence by about 78% compared to episodic treatment over a six-month period. Daily suppressive therapy also dramatically reduces viral shedding. In a large trial of couples where one partner had genital HSV-2, daily valacyclovir reduced the days with detectable genital shedding from about 11% to 3%, and cut the rate of transmission to the uninfected partner roughly in half.
Suppressive therapy is especially useful for people with frequent outbreaks or for reducing transmission risk in serodiscordant couples (where one partner has herpes and the other does not). But it is medication management, not a cure. Stop the daily pill, and the virus can reactivate as before.
When Herpes Becomes Dangerous
For most people with healthy immune systems, herpes is a manageable nuisance. But there are situations where it becomes genuinely dangerous. In immunocompromised patients, HSV infections can present atypically, with granulomatous or linear erosive lesions, deep tissue involvement, and resistance to standard antiviral drugs. A case series documented necrotizing cutaneous HSV infections in patients with blood cancers or histories of chemoradiation, all of whom had refractory disease that did not respond to typical acyclovir-based therapy.
Herpes keratitis, infection of the cornea, is another serious complication. Recurrent HSV-1 reactivation in the eye can cause corneal scarring, abnormal blood vessel growth, and eventually blindness. Even after corneal transplant surgery, the latent virus can reactivate in the new tissue. In patients who received corneal transplants without antiviral prophylaxis, one study found a recurrence rate of 44% within two years.
Neonatal herpes, transmitted from mother to baby during delivery, is rare but can be devastating, causing encephalitis and organ damage. And HSV-1 encephalitis in adults, though uncommon, is a life-threatening emergency. About a third of HSV-1 encephalitis cases occur during primary infection rather than reactivation.
Lysine and Other Non-Drug Approaches
The amino acid L-lysine is one of the most commonly discussed “natural” remedies for herpes. The theory is that lysine competes with another amino acid, arginine, which the virus needs to replicate. The evidence, however, is mixed at best. A review of available studies found that lysine supplementation at doses below 1 gram per day, without also restricting dietary arginine, appears to be ineffective for preventing or treating herpes outbreaks. Only at doses above 3 grams per day did patients report subjective improvement in their experience of the disease, and the quality of evidence behind even that finding is limited.
Stress management, adequate sleep, and sun protection are commonly recommended lifestyle approaches for reducing outbreak frequency, and they align with what we know about reactivation triggers. But none of these measures eliminate the latent virus, and none have been rigorously tested in the way antiviral drugs have. They are reasonable complementary strategies, not replacements for antiviral therapy in people who need it.
The Psychological Weight of a Lifelong Diagnosis
For many people, the hardest part of herpes is not the physical symptoms but the emotional and social burden. The stigma attached to genital herpes is disproportionate to the actual medical severity of the condition for most people. Research on psychological adjustment in women with genital herpes found that perceived stigma, along with coping strategies and sources of social support, accounted for about two-thirds of the variation in quality of life scores. Acceptance-based coping and support from online communities were associated with better outcomes, while denial-based coping was associated with worse adjustment.
The belief that herpes “clears up on its own” can cut both ways psychologically. On one hand, it may reduce anxiety in someone who has had one outbreak and never has another. On the other, it can lead to shock and distress when someone learns, perhaps years later, that they still carry the virus and can still transmit it. Honest understanding of what lifelong latency means, and what it does not mean, tends to produce better long-term adjustment than either catastrophizing or denial.
Is a Cure on the Horizon
The reason herpes has been incurable is that no drug can reach the latent viral DNA inside neurons. But gene-editing technologies are beginning to change that picture. Researchers have developed an approach using engineered meganucleases, a type of molecular scissor, delivered into nerve cells by viral vectors. In mouse models, this strategy eliminated over 90% of latent HSV-1 DNA in orofacial infections and up to 97% in genital infections.
A separate line of research using CRISPR-Cas9 gene editing has shown promising results in human cerebral organoids, miniature lab-grown models of brain tissue. Targeting key viral genes with CRISPR significantly reduced viral rebound in organoids that were latently infected with HSV-1.
These results are exciting but early. Moving from mouse ganglia and lab-grown tissue to a safe, effective treatment in living humans involves enormous challenges, including making sure the editing tools reach enough neurons, do not cut the wrong DNA, and do not cause dangerous immune reactions. No gene-editing therapy for herpes has entered large-scale human trials yet. The most realistic near-term hope for a medical advance may be a therapeutic vaccine. Unlike preventive vaccines that stop infection before it starts, therapeutic vaccines aim to boost the immune response in people already infected, reducing reactivation and shedding. Research on therapeutic herpesvirus vaccines has shown that T-cell immunity, rather than antibody levels measured in the blood, is the key correlate of protection, a lesson learned from the success of the zoster (shingles) vaccine.
How HSV Compares to Its Viral Cousin
Herpes simplex viruses belong to the same family as varicella-zoster virus, the cause of chickenpox and shingles. All three establish latency in nerve cells and can reactivate later. But their patterns differ in interesting ways. HSV tends to reactivate frequently but usually produces localized, relatively mild disease in healthy people. VZV, by contrast, typically reactivates only once, decades after the initial chickenpox infection, but when it does, the resulting shingles can be extremely painful and debilitating.
The triggers also differ. HSV reactivation is associated with everyday stressors and occurs more often in younger adults, while VZV reactivation is primarily driven by the age-related decline of virus-specific T cells and is far more common in older adults. Understanding these differences matters because it illustrates a broader truth about herpesviruses: the same fundamental strategy of latency and reactivation plays out very differently depending on the specific virus and the host’s immune landscape. None of them “clear up” in any meaningful sense. They persist, and the immune system manages rather than eliminates them.